Vivo Capital Fund Viii, L.p. - Net Worth and Insider Trading
Vivo Capital Fund Viii, L.p. Net Worth
The estimated net worth of Vivo Capital Fund Viii, L.p. is at least $40 Million dollars as of 2024-11-05. Vivo Capital Fund Viii, L.p. is the 10% Owner of Terns Pharmaceuticals Inc and owns about 2,675,133 shares of Terns Pharmaceuticals Inc (TERN) stock worth over $19 Million. Vivo Capital Fund Viii, L.p. is the 10% Owner of Crinetics Pharmaceuticals Inc and owns about 298,625 shares of Crinetics Pharmaceuticals Inc (CRNX) stock worth over $17 Million. Vivo Capital Fund Viii, L.p. is also the 10% Owner of Bolt Biotherapeutics Inc and owns about 3,781,837 shares of Bolt Biotherapeutics Inc (BOLT) stock worth over $2 Million. Besides these, Vivo Capital Fund Viii, L.p. also holds Aligos Therapeutics Inc (ALGS) , BioPharmX Corp (BPMX) , IPI Legacy Liquidation Co (IMPLQ) . Details can be seen in Vivo Capital Fund Viii, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Vivo Capital Fund Viii, L.p. has not made any transactions after 2023-12-19 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Vivo Capital Fund Viii, L.p.
Vivo Capital Fund Viii, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Vivo Capital Fund Viii, L.p. owns 8 companies in total, including Aligos Therapeutics Inc (ALGS) , Crinetics Pharmaceuticals Inc (CRNX) , and Kadmon Holdings Inc (KDMN) among others .
Click here to see the complete history of Vivo Capital Fund Viii, L.p.’s form 4 insider trades.
Insider Ownership Summary of Vivo Capital Fund Viii, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ALGS | Aligos Therapeutics Inc | 2020-10-20 | 10 percent owner |
| CRNX | Crinetics Pharmaceuticals Inc | 2020-04-17 | 10 percent owner |
| KDMN | Kadmon Holdings Inc | 2019-01-07 | 10 percent owner |
 | | 2018-01-24 | 10 percent owner |
| | 2017-04-28 | 10 percent owner |
| | 2023-12-19 | 10 percent owner |
| | 2023-11-21 | 10 percent owner |
| | 2022-08-12 | 10 percent owner |
Vivo Capital Fund Viii, L.p. Latest Holdings Summary
Vivo Capital Fund Viii, L.p. currently owns a total of 6 stocks. Among these stocks, Vivo Capital Fund Viii, L.p. owns 2,675,133 shares of Terns Pharmaceuticals Inc (TERN) as of February 9, 2021, with a value of $19 Million and a weighting of 47.31%. Vivo Capital Fund Viii, L.p. owns 298,625 shares of Crinetics Pharmaceuticals Inc (CRNX) as of April 17, 2020, with a value of $17 Million and a weighting of 42.24%. Vivo Capital Fund Viii, L.p. also owns 3,781,837 shares of Bolt Biotherapeutics Inc (BOLT) as of November 21, 2023, with a value of $2 Million and a weighting of 6.25%. The other 3 stocks Aligos Therapeutics Inc (ALGS) , BioPharmX Corp (BPMX) , IPI Legacy Liquidation Co (IMPLQ) have a combined weighting of 4.2% among all his current holdings.
Latest Holdings of Vivo Capital Fund Viii, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| TERN | Terns Pharmaceuticals Inc | 2021-02-09 | 2,675,133 | 7.06 | 18,884,834 |
| CRNX | Crinetics Pharmaceuticals Inc | 2020-04-17 | 298,625 | 56.46 | 16,860,368 |
| BOLT | Bolt Biotherapeutics Inc | 2023-11-21 | 3,781,837 | 0.66 | 2,496,012 |
| ALGS | Aligos Therapeutics Inc | 2020-10-20 | 141,881 | 9.53 | 1,352,594 |
| BPMX | BioPharmX Corp | 2017-04-28 | 46,988 | 6.12 | 287,567 |
| IMPLQ | IPI Legacy Liquidation Co | 2023-12-19 | 2,309,789 | 0.02 | 34,647 |
Holding Weightings of Vivo Capital Fund Viii, L.p.
Vivo Capital Fund Viii, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Vivo Capital Fund Viii, L.p. has made a total of 1 transactions in Terns Pharmaceuticals Inc (TERN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Terns Pharmaceuticals Inc is the acquisition of 475,000 shares on February 9, 2021, which cost Vivo Capital Fund Viii, L.p. around $8 Million.
According to the SEC Form 4 filings, Vivo Capital Fund Viii, L.p. has made a total of 6 transactions in Crinetics Pharmaceuticals Inc (CRNX) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Crinetics Pharmaceuticals Inc is the sale of 330,598 shares on April 17, 2020, which brought Vivo Capital Fund Viii, L.p. around $5 Million.
According to the SEC Form 4 filings, Vivo Capital Fund Viii, L.p. has made a total of 4 transactions in Bolt Biotherapeutics Inc (BOLT) over the past 5 years, including 1 buys and 3 sells. The most-recent trade in Bolt Biotherapeutics Inc is the sale of 3,400 shares on November 21, 2023, which brought Vivo Capital Fund Viii, L.p. around $3,060.
More details on Vivo Capital Fund Viii, L.p.'s insider transactions can be found in the Insider Trading History of Vivo Capital Fund Viii, L.p. table.Insider Trading History of Vivo Capital Fund Viii, L.p.
- 1
Vivo Capital Fund Viii, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Vivo Capital Fund Viii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Vivo Capital Fund Viii, L.p. is 7.76%. GuruFocus also compares Vivo Capital Fund Viii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Vivo Capital Fund Viii, L.p. within 3 months outperforms 1 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Vivo Capital Fund Viii, L.p.'s insider trading performs compared to the benchmark.
Performance of Vivo Capital Fund Viii, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 3.26 | | | | | |
| Relative Return to S&P 500(%) | 2.63 | | | | | |
Vivo Capital Fund Viii, L.p. Ownership Network
Ownership Network List of Vivo Capital Fund Viii, L.p.
Ownership Network Relation of Vivo Capital Fund Viii, L.p.
Vivo Capital Fund Viii, L.p. Owned Company Details
What does Aligos Therapeutics Inc do?
Who are the key executives at Aligos Therapeutics Inc?
Vivo Capital Fund Viii, L.p. is the 10 percent owner of Aligos Therapeutics Inc. Other key executives at Aligos Therapeutics Inc include 10 percent owner Roche Holding Ltd , 10 percent owner Roche Finance Ltd , and Chief Medical Officer Matthew W. Mcclure .
Aligos Therapeutics Inc (ALGS) Insider Trades Summary
Over the past 18 months, Vivo Capital Fund Viii, L.p. made no insider transaction in Aligos Therapeutics Inc (ALGS). Other recent insider transactions involving Aligos Therapeutics Inc (ALGS) include a net purchase of 7,933,601 shares made by Carole Nuechterlein ,
In summary, during the past 3 months, insiders sold 0 shares of Aligos Therapeutics Inc (ALGS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aligos Therapeutics Inc (ALGS) were sold and 317,344 shares were bought by its insiders, resulting in a net purchase of 317,344 shares.
Aligos Therapeutics Inc (ALGS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aligos Therapeutics Inc Insider Transactions
Vivo Capital Fund Viii, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Vivo Capital Fund Viii, L.p.. You might contact Vivo Capital Fund Viii, L.p. via mailing address: 505 Hamilton Avenue, Suite 200, Palo Alto Ca 94301.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
